Kyntra Bio, Inc. Common Stock — チャート、価格、ニュース (NASDAQ:KYNB)

チャート全体を表示

Financials

概要明細書統計

期次年次

Market Capitalization 29.83 M
Employee 34
Founded 1993
CEO N/A
Website www.kyntrabio.com
Headquarter California, United States
FIGI BBG000FW5ZL6
Industry Technology

総売上高

当期純利益

1株当たり基本利益（基本EPS）

有利子負債合計

フリーキャッシュフロー

現金および現金同等物

29.83 M 時価総額

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.